Sitagliptyna — nowoczesny lek w terapii cukrzycy typu 2

The dipeptidyl peptidase inhibitors are a new class of anti-hyperglycaemic agents with unique incretin action. Sitagliptin, representative of this group, effectively improves glycaemic control, reducing both fasting and postprandial glucose levels to lower HbA1c levels. It is characterizes by safe adverse event profile with apparently low risk of hypoglycemia and without weight gain. It is recommended generally in type 2 diabetes combination therapy (in line with sulphonylureas) in ineffectiveness of metformin monotherapy. ( Forum Zaburzen Metabolicznych 2011, vol. 2, no 1, 1–10)